ArticleMolecular psychiatry2026
Ethanolamine as a potential biomarker and therapeutic target for depressive disorder.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
We investigated cerebrospinal fluid (CSF) ethanolamine (EA) levels in major depressive disorder (MDD), to validate our previous findings on EA (Ogawa et al., 2015) and broaden its biological context and translational relevance. Using human samples (sets A-C) and animal models, we explored the implications for replication, translational potential, therapeutic development, and mechanistic insight. In set A (n = 380), CSF EA levels were low in patients with MDD (P = 0.00047, Cohen's d = -0.59), negatively correlating with depression severity (Spearman's ρ = -0.29, P = 0.00015) and positively correlating with CSF homovanillic acid (partial r = 0.40, P = 6.7E - 8) and 5-hydroxyindoleacetic acid levels (partial r = 0.26, P = 0.00064). Patients with moderate-to-severe depression showed large effects regardless of medication (Cohen's d = -1.27 to -1.14). In set B (n = 13), CSF EA levels were significantly increased in patients who received electroconvulsive therapy (P = 0.0071; Cohen's d = 0.90), which was linked to Hamilton Depression Rating Scale subscale score recovery. In set C (n = 66), a novel multicenter-collected sample set, CSF EA levels were low in patients with MDD (P = 0.0037; Cohen's d = -0.91). Rats receiving 0.5 or 1.0 mg/kg lipopolysaccharide intraperitoneally for 7 days showed significantly reduced CSF EA levels (P = 0.014; Cohen's d = -1.52 and 0.00020; d = 2.31, respectively) and depressive-, anxiety-, and anhedonia-like behaviors. Rats orally administered EA for 4 weeks showed significant antidepressant-like behaviors (P = 0.016; Cohen's d = -1.36). Proteomic and bioinformatic analyses revealed 40 proteins that were significantly correlated with CSF EA levels. The top hit protein was CHL1 (partial r = 0.42, P = 1.5E - 9), and the axon guidance pathway was the most enriched (P = 3.4E - 20). EA is a potential CSF biomarker for mental state evaluation, treatment response, subtyping, and validation of MDD animal models and a promising research tool for developing a new classification framework for psychiatric disorders and novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.